Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (141-150 of 250) with videos related to

Pageof 25
Sort By:
Neurodegenerative Disease Management|October 24, 2022
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summaryPeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Neurology|July 30, 2020
Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndromeOlivier Outteryck, Renaud Lopes, Élodie Drumez, et al.
The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.
International Journal of Molecular Sciences|October 14, 2022
Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple SclerosisBénédicte Oxombre, Fahima Madouri, Anne-Sophie Journé, et al.
Neurogenetics|January 6, 2007
NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in EuropeStephan Klebe, Arnaud Lacour, Alexandra Durr, et al.
Archives of Neurology|July 16, 2008
Optical coherence tomography in neuromyelitis opticaJérôme de Seze, Frederic Blanc, Luc Jeanjean, et al.
Eclinicalmedicine|March 30, 2026
Digital patient experience tools in multiple sclerosis: a landscape analysis of the global Patient-Reported Outcomes in Multiple Sclerosis (PROMS) initiativeVasilis-Spyridon Tseriotis, Liesbet M Peeters, Lotte Geys, et al.
Clinical Drug Investigation|October 25, 2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY StudyShehzad Ali, Noman Paracha, Stuart Cook, et al.
Alzheimer'S Research & Therapy|April 22, 2023
Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trialBruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, et al.
Archives of Neurology|July 13, 2011
A benign form of neuromyelitis optica: does it exist?Nicolas Collongues, Philippe Cabre, Romain Marignier, et al.
Pageof 25

Showing results (141-150 of 250) with videos related to

Sort By:
Pageof 25
Neurodegenerative Disease Management|October 24, 2022
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summaryPeter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Neurology|July 30, 2020
Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndromeOlivier Outteryck, Renaud Lopes, Élodie Drumez, et al.
The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.
International Journal of Molecular Sciences|October 14, 2022
Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple SclerosisBénédicte Oxombre, Fahima Madouri, Anne-Sophie Journé, et al.
Neurogenetics|January 6, 2007
NIPA1 (SPG6) mutations are a rare cause of autosomal dominant spastic paraplegia in EuropeStephan Klebe, Arnaud Lacour, Alexandra Durr, et al.
Archives of Neurology|July 16, 2008
Optical coherence tomography in neuromyelitis opticaJérôme de Seze, Frederic Blanc, Luc Jeanjean, et al.
Eclinicalmedicine|March 30, 2026
Digital patient experience tools in multiple sclerosis: a landscape analysis of the global Patient-Reported Outcomes in Multiple Sclerosis (PROMS) initiativeVasilis-Spyridon Tseriotis, Liesbet M Peeters, Lotte Geys, et al.
Clinical Drug Investigation|October 25, 2011
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY StudyShehzad Ali, Noman Paracha, Stuart Cook, et al.
Alzheimer'S Research & Therapy|April 22, 2023
Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trialBruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, et al.
Archives of Neurology|July 13, 2011
A benign form of neuromyelitis optica: does it exist?Nicolas Collongues, Philippe Cabre, Romain Marignier, et al.
Pageof 25